ESR2 and cancer: For example, Raloxifene has recently demonstrated antitumor effects in various ERα-negative cancer models, including TNBC [12], hepatocellular carcinoma [13], pancreatic ductal adenocarcinoma [14], and AR-negative prostate cancer [15], by activating ERβ.